X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, once-daily oral antagonist of the CRF1 receptor, which is being developed for the treatment of adult classic congenital adrenal hyperplasia (CAH)
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, once-daily oral antagonist of the CRF1 receptor. It is being evaluated in phase 2 clinical trials for the treatment of congenial adrenal hyperplasia.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the CRF1 receptor, which is investigated for the treatment of adult Classic Congenital Adrenal Hyperplasia.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, including SPR001 (tildacerfont) and for working capital and other general corporate purposes.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: 5am Ventures
Deal Size: $53.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 09, 2023
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA axis.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kaken Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Partnership January 05, 2023
Details:
Spruce is developing its wholly-owned product candidate, SPR001 (tildacerfont), as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH).
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Tildacerfont has been evaluated in 171 patients across seven clinical trials in which it has been generally well tolerated. No drug-related serious adverse events have been reported related to tildacerfont treatment.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo-controlled, late stage clinical studies in adults with Classic CAH.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
The proceeds will be used to further fund the clinical development of the company’s lead product, tildacerfont, in classic congenital adrenal hyperplasia (CAH) and other conditions.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $88.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
